TABLE 1.
Assessment of HDPC efficacy against L. infantum infection in BALB/c mice: experimental protocolsa
| Protocol | Treatment group (no. of mice) | Treatment period (dpi)b | Day(s) of amastigote burden evaluation (dpi) |
|---|---|---|---|
| 1 | HDPC (11) | D7–D11 | D14 |
| MEGAN (10) | |||
| NTC (10) | |||
| 2 | HDPC (10) | D42–D46 | D49 |
| MEGAN (10) | |||
| NTC (10) | |||
| 3 | HDPC (11)c | D28–D32 | D42, D63, D84 |
| NTC (11)c | D42, D63, D84 |
a
Mice were intravenously inoculated with 108 stationary-phase L. infantum promastigotes/mouse. The day of infection is termed D0. Mice were randomly assigned to groups of 10 or 11 mice and were treated for 5 days with HDPC (20 mg/kg of body weight/day, oral administration) or MEGAN (200 mg/kg of body weight, subcutaneous injection) or were left untreated.
b
dpi, day post infection.
c
Three groups of 11 mice were used.